There has been some selling insider activity on BeiGene, Ltd. – American Deposi (NASDAQ:BGNE) recently. Donald W. Glazer, Director sold $778,752 worth of shares at an average price of $72.04 on Mon the 10th. That brings the Director’s holdings to $0 as recorded in a recent Form 4 SEC filing. John Oyler, CEO sold $4,394,085 worth of shares at a price of $44.61 on Fri the 23rd. Oyler now owns $2,089,532 of stock per an SEC filing yesterday.
Director Xiaodong Wang let go of 5,539 shares at an average price of $40.00 on June 2nd. That brings Wang’s holdings to $2,200,000 as reported to the SEC.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. Its cancer biology platform addresses the position of tumor-immune system interactions and the value of primary biopsies in developing new models..
These funds have also shifted positions in (BGNE). Bank Of Montreal /can/ added to its ownership by buying 14,128 shares an increase of 315.2% from 03/31/2017 to 06/30/2017. Bank Of Montreal /can/ owns 18,610 shares worth $837,000. The total value of its holdings increased 410.4%. Morgan Stanley expanded its investment by buying 400 shares an increase of 242.4% in the quarter. Morgan Stanley claims 565 shares valued at $21,000. The value of the position overall is up by 320.0%.
Tower Research Capital LLC (trc) grew its holdings by buying 1,525 shares an increase of 385.1%. Tower Research Capital LLC (trc) now holds 1,921 shares with a value of $70,000. The value of the position overall is up by 483.3%. As of the end of the quarter Goldman Sachs Group Inc had disposed of a total of 259 shares trimming its stake by 1.4%. The value of the investment in BeiGene, Ltd. – American Deposi went from $567,000 to $674,000 a change of $107,000 quarter over quarter.
On September 22, 2016 Maxim Group added the stock to its research portfolio by announcing an initial rating of “Buy”. On February 29 analysts at Morgan Stanley began coverage of the stock with a rating of “Overweight”.
Equity analyst Cowen & Company initiated coverage on the stock giving it an initial rating of “Outperform”. Baird began coverage with an initial rating of “Outperform” and price target of $44.00.
On February 29, 2016 Goldman Sachs issued its first research report on the stock setting a rating of “Buy” and projecting a price target of $33.00.
In the market the company is trading down since yesterday’s close of $73.89. Shares are trading at $72.86 slightly over $40.06, the 50 day moving average and which is slightly above the 200 day moving average of $37.01. The 50 day moving average went up $32.80 or +81.90% whereas the 200 day moving average was up $35.85 or +96.89%.
In the latest earnings report the EPS was $-4.18 and is expected to be $-3.41 for the current year with 39,725,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $0.33 with next year’s EPS anticipated to be $-5.20.
Short traders are more bearish on BeiGene, Ltd. – American Deposi of late if you take note of the increase in short interest. The firm saw a rise in short interest from June 15, 2017 to May 31, 2017 of 4.61%. Short shares grew 55,122 over that period. With short interest at 1,250,371 and short average daily volume at 56,382, days to cover is 22.2 and the percentage of shorted shares was 0.03% on May 31.